CalciMedica (CALC) vs Curanex Pharmaceuticals (CURX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CalciMedica is the larger company by market cap ($8.7 million vs $8.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | CURX |
|---|---|---|
| Share price | $1.28 | $5.23 |
| Market cap | $8.74M | $8.20M |
| 1-day change | -1.54% | +9.87% |
| YTD return | -96.05% | — |
| 1-year return | -91.84% | — |
| EPS (TTM) | $-6.85 | $-7.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.00 | $16.94 |
| 52-week low | $1.28 | $3.58 |
| Distance from 52-week high | -96.44% | -69.13% |
| Analyst consensus | none | — |
| Avg. price target upside | +3806.25% | — |
| Average volume | 75.54K | 19.85K |
| Shares outstanding | 6.83M | 1.57M |
| Employees | 15 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CALC vs CURX FAQ
Which is bigger, CalciMedica or Curanex Pharmaceuticals?
CalciMedica (CALC) is larger, with a market capitalization of $8.74M compared with $8.20M for Curanex Pharmaceuticals (CURX).
Are CalciMedica and Curanex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.